BioSpace News Archive

Merck posted a rare defeat Wednesday for its blockbuster Keytruda (pembrolizumab) in prostate cancer while simultaneously announcing a victory in biliary tract cancer.

Wet labs and dry labs perform vastly different functions for biotechs and research organizations, and thus require different skill sets. Read on to find out which lab environment is right for you.

The FDA’s approval of Biogen and Eisai’s Leqembi and subsequent decision not to approve Eli Lilly’s donanemab have sparked debate anew about the anti-amyloid theory in Alzheimer’s.

Small Pharma announced positive top-line results Wednesday from a Phase IIa study evaluating a short-duration psychedelic for major depressive disorder.

Three venture capitalists debuted Dimension I Wednesday, a new fund with $350 million to fuel modern biotech.

Sosei Group Corporation will announce its earnings results and present operational highlights for the 12 months ended 31 December 2022 on Tuesday, 14 February 2023.

POXEL SA announced that European Commission has granted orphan drug designation for PXL770 and PXL065 for the treatment of adrenoleukodystrophy.

BioArctic AB will publish the company’s fourth quarter report for October - December 2022 on Friday, February 3, 2022, at 08:00 a.m. CET.

Immuron Limited today announces that a response letter has been submitted to the US Food and Drug Administration (FDA). Immuron has previously reported feedback was received from the FDA following a review of the Investigational New Drug (IND) application (ASX announcement July 26, 2022) of a new oral therapeutic targeting Campylobacter and ETEC developed in collaboration with Immuron.

Collaboration to seed critical progress in radiation oncology for patients with lung cancer.